ATXS
Price
$7.00
Change
+$0.41 (+6.22%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
395.04M
69 days until earnings call
GOSS
Price
$2.58
Change
-$0.01 (-0.39%)
Updated
Sep 3 closing price
Capitalization
586.64M
63 days until earnings call
Interact to see
Advertisement

ATXS vs GOSS

Header iconATXS vs GOSS Comparison
Open Charts ATXS vs GOSSBanner chart's image
Astria Therapeutics
Price$7.00
Change+$0.41 (+6.22%)
Volume$20.29K
Capitalization395.04M
Gossamer Bio
Price$2.58
Change-$0.01 (-0.39%)
Volume$3.31M
Capitalization586.64M
ATXS vs GOSS Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. GOSS commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and GOSS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ATXS: $6.59 vs. GOSS: $2.59)
Brand notoriety: ATXS and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 130% vs. GOSS: 258%
Market capitalization -- ATXS: $395.04M vs. GOSS: $586.64M
ATXS [@Biotechnology] is valued at $395.04M. GOSS’s [@Biotechnology] market capitalization is $586.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, GOSS is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while GOSS’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 3 bearish.
  • GOSS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than GOSS.

Price Growth

ATXS (@Biotechnology) experienced а -1.20% price change this week, while GOSS (@Biotechnology) price change was +2.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

GOSS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($587M) has a higher market cap than ATXS($395M). GOSS YTD gains are higher at: 186.314 vs. ATXS (-26.286). GOSS (-128.6M) and ATXS (-131.42M) have comparable annual earnings (EBITDA) . ATXS has more cash in the bank: 259M vs. GOSS (213M). ATXS has less debt than GOSS: ATXS (4.77M) vs GOSS (203M). GOSS has higher revenues than ATXS: GOSS (40.2M) vs ATXS (0).
ATXSGOSSATXS / GOSS
Capitalization395M587M67%
EBITDA-131.42M-128.6M102%
Gain YTD-26.286186.314-14%
P/E RatioN/AN/A-
Revenue040.2M-
Total Cash259M213M122%
Total Debt4.77M203M2%
FUNDAMENTALS RATINGS
ATXS vs GOSS: Fundamental Ratings
ATXS
GOSS
OUTLOOK RATING
1..100
7521
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6135
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (56) in the Biotechnology industry is in the same range as GOSS (56) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to GOSS’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to GOSS’s over the last 12 months.

ATXS's SMR Rating (98) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ATXS (61) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ATXS’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSGOSS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEOBF1.51N/A
N/A
Mesoblast Ltd.
RSGOF0.17N/A
N/A
RESOURO STRATEGIC METALS INC.
JCYCF21.49N/A
N/A
Jardine Cycle & Carriage Limited
QNBC35.60-0.09
-0.25%
QNB Corp.
SNEJF28.41-0.59
-2.04%
Sony Group Corporation

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with CRNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+6.63%
CRNX - ATXS
53%
Loosely correlated
+7.45%
XENE - ATXS
50%
Loosely correlated
+1.52%
DNLI - ATXS
50%
Loosely correlated
+1.18%
NRIX - ATXS
50%
Loosely correlated
-2.46%
OCUL - ATXS
50%
Loosely correlated
+4.01%
More

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with ABEO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+4.86%
ABEO - GOSS
41%
Loosely correlated
+0.29%
SLDB - GOSS
37%
Loosely correlated
-0.91%
ATXS - GOSS
34%
Loosely correlated
+6.63%
XNCR - GOSS
34%
Loosely correlated
+5.17%
CRBU - GOSS
34%
Loosely correlated
+0.53%
More